Stocks · News reference
8-K filing — PTC THERAPEUTICS, INC. (PTCT)
Filed: 2026-08-13 AccNo: 0001104659-26-095424 Size: 208 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 11:00 AM
- Checked
- Aug 13, 2026, 11:00 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
Read original at benzingaPTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
Read original at benzingaWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
Read original at benzinga